LON:FUM - Futura Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 24 +1.50 (+6.67 %) (As of 05/23/2019 04:00 PM ET)Previous CloseGBX 22.50Today's RangeGBX 19.01 - GBX 24.5052-Week RangeGBX 5.65 - GBX 37.76Volume1.67 million shsAverage Volume415,619 shsMarket Capitalization£49.12 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Futura Medical plc develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual healthcare and pain relief management. The company offers CSD500, a condom that incorporates an erectogenic gel to help men maintain a firmer erection during intercourse whilst wearing a condom. It is also developing MED2002, a topical gel applied directly to the penis for the treatment of male erectile dysfunction that is in Final Phase III program. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; TIB200, a topical ibuprofen pain relief gel; and SPR300, a topical methyl salicylate pain relief gel. It operates in the Middle East/ROW, the United States, and Europe. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom. Receive FUM News and Ratings via Email Sign-up to receive the latest news and ratings for FUM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:FUM Previous Symbol CUSIPN/A CIKN/A Webhttp://www.futuramedical.com/ Phone+44-1483-685670Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£170.00 Price / Sales288,931.76 Cash FlowGBX 4.82 per share Price / Cash Flow4.98 Book ValueGBX 4.30 per share Price / Book5.58Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares204,660,000Market Cap£49.12 million Next Earnings DateN/A OptionableNot Optionable Futura Medical (LON:FUM) Frequently Asked Questions What is Futura Medical's stock symbol? Futura Medical trades on the London Stock Exchange (LON) under the ticker symbol "FUM." Has Futura Medical been receiving favorable news coverage? Media stories about FUM stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Futura Medical earned a news impact score of -1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Futura Medical's key competitors? Some companies that are related to Futura Medical include Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Cathay International (CTI), Patrys (PAB), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP), NanoViricides (NNVC), Sareum (SAR), China Pharma (CPHI), N4 Pharma (N4P) and Bayer (BAYN). What other stocks do shareholders of Futura Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Futura Medical investors own include Indivior (INDV), Bigblu Broadband (BBB), Directa Plus (DCTA), Genel Energy (GENL), Lakehouse (LAKE), Petrel Resources (PET), Tullow Oil (TLW), The People's Operator (TPOP), CityFibre Infrastructure (CITY) and Premier Foods (PFD). Who are Futura Medical's key executives? Futura Medical's management team includes the folowing people: Mr. James Henry Barder, CEO & Exec. Director (Age 59)Mr. Kenneth William James, Head of R&D and Exec. Director (Age 66)Ms. Angela Hildreth, COO, Fin. Director, Company Sec. & DirectorDr. William Duncan Potter, Chief Scientific Officer & Adviser to the Board (Age 71) How do I buy shares of Futura Medical? Shares of FUM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Futura Medical's stock price today? One share of FUM stock can currently be purchased for approximately GBX 24. How big of a company is Futura Medical? Futura Medical has a market capitalization of £49.12 million and generates £170.00 in revenue each year. Futura Medical employs 15 workers across the globe. What is Futura Medical's official website? The official website for Futura Medical is http://www.futuramedical.com/. How can I contact Futura Medical? Futura Medical's mailing address is 40 Surrey Technology Centre, Occam Road, GUILDFORD, GU2 7YG, United Kingdom. The company can be reached via phone at +44-1483-685670. MarketBeat Community Rating for Futura Medical (LON FUM)Community Ranking: 1.9 out of 5 ()Outperform Votes: 105 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 281MarketBeat's community ratings are surveys of what our community members think about Futura Medical and other stocks. Vote "Outperform" if you believe FUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FUM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: How do candlesticks reflect price movement? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.